NASDAQ:ATRC - AtriCure Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$31.73 +0.51 (+1.63 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$31.73
Today's Range$31.30 - $31.97
52-Week Range$14.88 - $36.49
Volume173,407 shs
Average Volume245,589 shs
Market Capitalization$1.20 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.22
AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.

Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ATRC
CUSIP04963C20
Phone513-755-4100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$174.72 million
Book Value$4.67 per share

Profitability

Net Income$-26,890,000.00

Miscellaneous

Employees570
Market Cap$1.20 billion
OptionableOptionable

AtriCure (NASDAQ:ATRC) Frequently Asked Questions

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

How were AtriCure's earnings last quarter?

AtriCure Inc. (NASDAQ:ATRC) posted its earnings results on Thursday, November, 1st. The medical device company reported ($0.24) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.22) by $0.02. The medical device company earned $49.90 million during the quarter, compared to the consensus estimate of $49.90 million. AtriCure had a negative net margin of 10.41% and a negative return on equity of 16.92%. The business's revenue was up 18.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.22) EPS. View AtriCure's Earnings History.

When is AtriCure's next earnings date?

AtriCure is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for AtriCure.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure issued an update on its FY 2019 earnings guidance on Monday, January, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $220-228 million, compared to the consensus revenue estimate of $222.8 million.AtriCure also updated its FY 2018 guidance to EPS.

What price target have analysts set for ATRC?

5 brokers have issued 12 month target prices for AtriCure's stock. Their forecasts range from $30.00 to $40.00. On average, they anticipate AtriCure's stock price to reach $35.75 in the next year. This suggests a possible upside of 12.7% from the stock's current price. View Analyst Price Targets for AtriCure.

What is the consensus analysts' recommendation for AtriCure?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AtriCure.

Has AtriCure been receiving favorable news coverage?

Press coverage about ATRC stock has been trending somewhat positive on Saturday, InfoTrie reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. AtriCure earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned press coverage about the medical device company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term.

Who are some of AtriCure's key competitors?

Who are AtriCure's key executives?

AtriCure's management team includes the folowing people:
  • Mr. Michael H. Carrel, CEO, Pres & Director (Age 48)
  • Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 44)
  • Mr. Douglas J. Seith, Chief Operating Officer (Age 53)
  • Mr. Salvatore Privitera, Chief Technology Officer (Age 52)
  • Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 41)

Who are AtriCure's major shareholders?

AtriCure's stock is owned by many different of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (1.76%). Company insiders that own AtriCure stock include Andrew L Lux, B Kristine Johnson, Elizabeth D Krell, Justin J Noznesky, M Andrew Wade, Mark A Collar and Regina E Groves. View Institutional Ownership Trends for AtriCure.

Which institutional investors are selling AtriCure stock?

ATRC stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have sold AtriCure company stock in the last year include Elizabeth D Krell, Justin J Noznesky and Mark A Collar. View Insider Buying and Selling for AtriCure.

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $31.73.

How big of a company is AtriCure?

AtriCure has a market capitalization of $1.20 billion and generates $174.72 million in revenue each year. The medical device company earns $-26,890,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. AtriCure employs 570 workers across the globe.

What is AtriCure's official website?

The official website for AtriCure is http://www.atricure.com.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.


MarketBeat Community Rating for AtriCure (NASDAQ ATRC)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  369 (Vote Outperform)
Underperform Votes:  241 (Vote Underperform)
Total Votes:  610
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe ATRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel